ReviewInternational journal of molecular sciences2016
Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type.
Review in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 162 citations in OpenAlex.
- Interplay of gut microbiota, immune cells and natural products in reshaping cancer immunotherapy.Frontiers in microbiology · 2026Review
- Transcriptomic identification of IL-17/FOS-associated signaling in dartos fascia remodeling of pediatric concealed penis.Frontiers in pediatrics · 2026Article
- Eosinophil extracellular traps formation is correlated with cancer prognosis by tumor microenvironment remodeling.Scientific reports · 2025Article
- Regulatory dynamics of Th17 lymphocytes in oral squamous cell carcinoma: immune modulation and emerging immunotherapies.Immunologic research · 2025Review
- Tracking inflammation status for improving patient prognosis: A review of current methods, unmet clinical needs and opportunities.Biotechnology advances · 2025Review
- Advances in mechanistic investigation and treatment of steroid-refractory ICI-induced liver injury.Clinical and experimental medicine · 2025Review
- Systematically investigate the mechanism underlying the therapeutic effect of emodin in treatment of prostate cancer.Discover oncology · 2025Article
- Roles of dendritic epidermal T cells in steady and different pathological states.Burns & trauma · 2025Review
- Article
- Narciclasine induces colon carcinoma cell apoptosis by inhibiting the IL-17A/Act1/TRAF6/NF-κB signaling pathway.Genes & diseases · 2024Article
- The role of IL-17 in the pathogenesis and treatment of glioblastoma-an update on the state of the art and future perspectives.Medical oncology (Northwood, London, England) · 2024Review
- Article
- Friend or Foe: Exploring the Relationship between the Gut Microbiota and the Pathogenesis and Treatment of Digestive Cancers.Microorganisms · 2024Review
- Tyrosine Kinase Inhibition Activates Intratumoral γδ T Cells in Gastrointestinal Stromal Tumor.Cancer immunology research · 2024Article
- The role of interleukin-17 in inflammation-related cancers.Frontiers in immunology · 2024Review
- Unveiling the immune symphony: decoding colorectal cancer metastasis through immune interactions.Frontiers in immunology · 2024Review
- The IL-17 family in diseases: from bench to bedside.Signal transduction and targeted therapy · 2023Review
- The prognostic and biology of tumour-infiltrating lymphocytes in the immunotherapy of cancer.British journal of cancer · 2023Review
- Signature construction and molecular subtype identification based on immune-related genes for better prediction of prognosis in hepatocellular carcinoma.BMC medical genomics · 2023Article
- Newly identified form of phenotypic plasticity of cancer: immunogenic mimicry.Cancer metastasis reviews · 2023Review
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The inflammatory process contributes to immune tolerance as well as to tumor progression and metastasis. By releasing extracellular signals, cancerous cells constantly shape their surrounding microenvironment through their interactions with infiltrating immune cells, stromal cells and components of extracellular matrix. Recently, the pro-inflammatory interleukin 17 (IL-17)-producing T helper lymphocytes, the Th17 cells, and the IL-17/IL-17 receptor (IL-17R) axis gained special attention. The IL-17 family comprises at least six members, IL-17A, IL-17B, IL-17C, IL-17D, IL-17E (also called IL-25), and IL-17F. Secreted as disulfide-linked homo- or heterodimers, the IL-17 bind to the IL-17R, a type I cell surface receptor, of which there are five variants, IL-17RA to IL-17RE. This review focuses on the current advances identifying the promoting role of IL-17 in carcinogenesis, tumor metastasis and resistance to chemotherapy of diverse solid cancers. While underscoring the IL-17/IL-17R axis as promising immunotherapeutic target in the context of cancer managing, this knowledge calls upon further in vitro and in vivo studies that would allow the development and implementation of novel strategies to combat tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.